Bausch Health Companies Inc. (TSE:BHC – Free Report) – Research analysts at Zacks Research lifted their FY2026 earnings estimates for Bausch Health Companies in a report issued on Tuesday, September 22nd. Zacks Research analyst Team now expects that the company will post earnings per share of $5.95 for the year, up from their prior forecast of $5.88. The consensus estimate for Bausch Health Companies’ current full-year earnings is $5.55 per share. Zacks Research also issued estimates for Bausch Health Companies’ Q1 2027 earnings at $1.18 EPS, Q2 2027 earnings at $1.28 EPS, Q3 2027 earnings at $1.50 EPS, Q4 2027 earnings at $1.43 EPS, FY2027 earnings at $5.40 EPS and Q2 2028 earnings at $1.21 EPS.
Bausch Health Companies (TSE:BHC – Get Free Report) last released its quarterly earnings data on Wednesday, July 29th. The company reported C$1.79 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 87.57% and a negative net margin of 12.02%.The company had revenue of C$4.05 billion for the quarter.
Get Our Latest Report on Bausch Health Companies
Bausch Health Companies Trading Down 1.6%
Shares of BHC opened at C$8.04 on Thursday. The company has a current ratio of 1.44, a quick ratio of 0.58 and a debt-to-equity ratio of -1,173.29. The stock has a market cap of C$3.01 billion, a PE ratio of -2.73, a PEG ratio of 0.21 and a beta of 0.71. Bausch Health Companies has a 1 year low of C$6.10 and a 1 year high of C$11.08. The stock has a 50 day simple moving average of C$8.32 and a 200-day simple moving average of C$7.65.
About Bausch Health Companies
Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.
Featured Articles
- Five stocks we like better than Bausch Health Companies
- Chips to Bots: Qualcomm’s Agentic AI Breakout
- Ciena Fell 40%—Now One Analyst Sees 50% Upside
- Energy Transfer Taps the AI Power Boom
- Viking’s Obesity Edge May Be Staying Power, Not Weight Loss
Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.
